What’s Going On With Candel Therapeutics Stock On Friday?
Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for non-metastatic prostate cancer. Exciting developments continue with updated data from ongoing phase 1b trial of CAN-3110 for recurrent high-grade glioma